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Impact of recurrent hypoglycemic stress on hindbrain 
A2 nerve cell energy metabolism and catecholamine 
biosynthesis: modulation by estradiol
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* Email: briski@ulm.edu
It is unclear if habituation of hindbrain A2 metabolo‑sensory neurons to recurrent insulin‑induced hypoglycemia (RIIH) correlates with 
estradiol‑dependent adjustments in energy metabolism that favor positive energy balance. Laser‑microdissected A2 cells from estradiol‑ 
or oil‑implanted ovariectomized female rats were analyzed by Western blot to assess effects of three prior daily insulin injections on 
basal and hypoglycemic patterns of catecholamine biosynthetic enzyme dopamine‑beta‑hydroxylase (DβH) and rate‑limiting energy 
pathway enzyme protein expression. Precedent hypoglycemia respectively decreased or increased baseline DβH expression in 
estradiol‑ (E) vs. oil (O)‑treated rats; this protein profile was further suppressed or augmented in those animals at 2 hr after re‑induction 
of hypoglycemia. These data suggest that estradiol may curtail A2 noradrenergic‑controlled functions both in the midst of and between 
hypoglycemic bouts. Results also show that prior hypoglycemia exposure upregulated A2 neuron glycolytic enzyme protein levels 
when E was present, and exerted differential effects on basal and hypoglycemia‑associated respiratory chain and fatty acid synthetic 
pathway enzyme expression. E may thus accordingly amplify glycolysis‑derived metabolites/energy, coupled with reduced reliance on 
oxidative phosphorylation, and activate the fatty acid synthetic pathway during RIIH. E may also be of benefit by preventing maladaptive 
reductions in A2 neuron Krebs cycle/electron transport enzyme expression during re‑exposure to hypoglycemia. Augmentation of 
negative energy balance during this recurring metabolic stress in the absence of E is a likely impetus for augmented vs. decreased A2 
signaling of energy imbalance by DβH in O vs. E rats during RIIH. 
Key words: ATP synthase‑alpha, dopamine‑beta‑hydroxylase, estradiol, laser‑catapult microdissection, recurrent insulin‑induced 
hypoglycemia, Western blot
INTRODUCTION
Hindbrain noradrenergic neurons, including the A2 
cell group located in the caudal dorsal vagal complex 
(cDVC), are involved in neural regulation of a wide array 
of physiological, behavioral and cognitive functions that 
maintain homeostasis, including control of emotional, 
endocrine, and autonomic responses to stress (Rinaman 
2011). A2 noradrenergic neurons are implicated in 
metabolo‑sensory function by characteristic biomarker 
expression, including glucokinase (Briski et al. 2009), 
the ATP‑dependent potassium channel, KATP (Briski et al. 
2009), and the ultra‑sensitive energy gauge adenosine 
5’‑monophosphate‑activated protein kinase (AMPK) 
(Cherian and Briski 2011, 2012). Evidence for glucose 
antimetabolite‑induced increases in Fos protein (Briski 
and Marshall 2000) and dopamine‑β‑hydroxylase (DβH) 
mRNA (Li et al. 2006) expression by A2 neurons provides 
proof of functional susceptibility to glucoprivation. 
A2 cells communicate hypoglycemia‑associated cell 
energy imbalance to the brain gluco‑regulatory 
network as insulin‑induced hypoglycemia‑associated 
patterns of hypothalamic metabolo‑sensory neuron 
AMPK activation, hypothalamic metabolic effector 
transmitter expression, and hypoglycemic hyperphagia 
are normalized by substrate fuel repletion of the cDVC 
(Gujar et al. 2014). Indeed, recent studies show that 
lactoprivic signaling from hindbrain to hypothalamus 
is selectively performed by A2 neurons (Shrestha et al. 
2014). Insulin‑dependent diabetes mellitus management 
is complicated by unremitting iatrogenic hypoglycemia 
and associated risk of brain dysfunction and injury. 
Evidence that hypoglycemia‑induced transcriptional 
activation in the male rat DVC is diminished by 
precedent exposure (Paranjape and Briski 2005) prompts 
speculation that metabolo‑sensory function in that site 
may be vulnerable to maladaptive desensitization to 
hypoglycemia (Smith and Amiel 2002). 
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The ovarian hormone estradiol is a potent stimulus for 
energy metabolism, enhancing substrate catabolism and 
oxidative respiration in the brain during bio‑energetic 
instability due to stroke (Chen et al. 2009). Estradiol is 
neuroprotective against singular bio‑energetic insults, but 
the impact of this hormone on neuron energy metabolism 
during recurring hypoglycemia is unclear. Estradiol delivery 
to the ovariectomized (OVX) female rat caudal hindbrain 
sustains uniformity of glycemic responses to repeated 
insulin dosing while vehicle controls exhibit delayed 
recovery from recurring hypoglycemia (Nedungadi and 
Briski 2012). Moreover, estradiol prevents habituation of 
hypoglycemia‑associated nerve cell Fos immunostaining 
in the DVC (Nedungadi et al. 2006). Estradiol may thus 
prevent cellular energy state adjustments over serial 
hypoglycemic bouts or, alternatively, may mask acquired 
cellular energy instability by promoting signals of 
energy balance. A2 neurons are likely direct targets for 
estradiol regulatory actions as these cells express estrogen 
receptor‑alpha and ‑beta proteins (Ibrahim et al. 2013). The 
current studies investigated the hypothesis that estradiol 
regulation of recurring hypoglycemia on A2 catecholamine 
neurotransmitter synthesis correlates with neuro‑protective 
effects on energy metabolic pathway function during and 
between bouts of hypoglycemia. This work had two aims: 
1) to determine how precedent hypoglycemia influences 
between‑hypoglycemia baseline expression of the 
catecholamine biosynthetic enzyme DβH and key metabolic 
enzyme proteins and 2) to ascertain how habituated 
basal profiles of these proteins react to re‑induction of 
hypoglycemia. Individual A2 neurons were identified in situ 
by immunocytochemistry and laser‑catapult microdissected 
from brains of estradiol‑ vs. vehicle‑implanted OVX rats after 
recovery from serial bouts of insulin‑induced hypoglycemia 
or during re‑exposure to hypoglycemia. Pooled A2 cells were 
evaluated by high‑sensitivity Western blotting to determine 
expression of rate‑limiting metabolic, e.g. glycolytic, 
tricarboxylic acid cycle, respiratory chain, and oxidative 
phosphorylation, acetyl‑CoA carboxylase‑AMPK‑fatty acid 
synthase pathway, and DβH enzyme protein expression 
between and during bouts of recurring hypoglycemia. 
METHODS AND MATERIALS
Animals
Adult female Sprague Dawley rats (225–250 g bw) were 
housed in groups of 2–3 per cage under a 14 hr light: 10 hr 
dark schedule (lights on at 05.00 hr), and gentled by daily 
handling. Rats were obtained from the ULM School of 
Pharmacy Vivarium in‑house breeding colony; breeders 
were purchased from Harlan Laboratories, Inc. Rats had 
unrestricted access to standard laboratory chow and water. 
All animal protocols were conducted in accordance with 
National Institutes of Health guidelines for care and use of 
laboratory rodents, and approved by the ULM Institutional 
Animal Care and Use Committee. On day 1, rats were 
anesthetized with ketamine/xylazine (0.1 mL/100 g bw sc; 
90 mg ketamine: 10 mg xylazine/mL; Henry Schein Inc., 
Melville, NY), then bilaterally OVX and implanted with 
a subcutaneous (sc) capsule (i.d. 1.58 mm, o.d. 3.18 mm; 
10 mm/100 g bw) filled with 17β estradiol‑3‑benzoate 
(E; 30 µg/mL safflower oil) or oil (O) (Briski et al. 2001). 
This hormone replacement strategy results in circulating 
plasma estradiol concentrations that mimic endogenous 
hormone concentrations measured on metestrus in 4‑day 
(Butcher et al. 1974) or on diestrus day‑2 in 5‑day cycling 
rats (Goodman 1978). After surgery, rats were transferred 
to individual cages. 
Experimental design
At 11.00 hr on days 6–8, groups of estradiol‑ and 
oil‑implanted OVX rats were injected sc with neutral 
protamine Hagedorn insulin (I; 12.5 U/kg/mL sc; Henry 
Schein Inc.; n=8 E‑implanted; n=8 O‑implanted) or vehicle 
(V; n=4 E‑implanted; n=4 O‑implanted). At 11.00 hr on day 
9, unfasted rats previously injected with V, one dose per day, 
on three previous days, received a final/fourth injection 
of V [n=4 E‑implanted (E‑V4); n=4 O‑implanted (O‑V4)]; at the 
same time, rats treated with 3 prior daily I injections were 
injected with V [n=4 E‑implanted (E‑I3V); n=4 O‑implanted 
(O‑I3V)] or I [n=4 E‑implanted (E‑I4); n=4 O‑implanted (O‑I4)] 
(Fig. 1). E‑V4 and O‑V4 groups were included in the design 
in order to assess effects of precedent hypoglycemia on 
baseline patterns of protein expression. Trunk blood and 
brain tissue were collected at 13.00 hr, at time point that 
coincides with the glucose nadir achieved by this insulin 
treatment paradigm (Paranjape and Briski 2005, Nedungadi 
et al. 2006). Rats were killed by rapid decapitation, a method 
approved by American Veterinary Medical Association 
Guidelines on Euthanasia (AVMA 2013). Dissected hindbrains 
were snap‑frozen in liquid nitrogen‑cooled isopentane. 
Western blot analysis of A2 nerve cell and cDVC 
metabolic and neurotransmitter biosynthetic 
enzyme protein expression
Serial 10 µm frozen sections of the cDVC (−14.36 to 
−14.86 mm posterior to bregma) were cut in a cryostat and 
processed for tyrosine hydroxylase (TH)‑immunoreactivity 
(‑ir) (Ibrahim et al. 2013). Only TH‑ir‑positive neurons 
characterized by an intact, visible nucleus and complete 
staining of the cytoplasmic compartment were individually 
removed from tissue sections using a P.A.L.M. UV‑A 
3_929_Tamrakar_v4.indd   32 01/04/17   15:10
A2 neuron adaptation to hypoglycemia 33Acta Neurobiol Exp 2017, 77: 31–44
microlaser (Carl Zeiss Microimaging, Inc., Thornwood, 
NY). The cDVC was bilaterally removed from serial 200 µm 
frozen hindbrain sections obtained from additional rats 
(n=4/treatment combination), using calibrated hollow 
micropunch needles (Stoelting, Inc., Kiel, WI); micropunched 
tissue was pooled for each rat. For each protein of interest, 
n=50 TH‑ir cells per treatment group (12–13 cells/protein/
rat; n=4 rats/treatment group) were collected in lysis 
buffer for immunoblotting; each protein was analyzed 
in triplicate in separate lysate pools. cDVC aliquots 
from each rat were pooled within each treatment group; 
pyruvate dehydrogenase (PDH), succinate dehydrogenase 
(SDH), and oxidative phosphorylation enzyme complexes 
were independently evaluated in triplicate in separate 
sample pools. Protein separation and transblotting were 
performed as described (Cherian and Briski 2011, 2012). 
The following primary antisera were used to analyze A2 
proteins: phosphofructokinase (PFKL; 30‑17/12108‑1101, 
ProSci., Inc., Poway, CA; rabbit polyclonal, 1:5000); pyruvate 
dehydrogenase (PDH E2/E3pb; MSP02/D0959‑ab110416, 
MitoSciences, Eugene, OR; mouse monoclonal, 1:5000); 
isocitrate dehydrogenase (IDH2; 26‑297/12108‑1101, 
ProSci.; rabbit polyclonal, 1:5000); alpha ketoglutarate 
dehydrogenase (OGDH; MS202/HCESHC‑ab110410, MitoSci.; 
mouse monoclonal, 1:5000); succinate dehydrogenase (SDH, 
Complex II‑C‑V‑alpha; MS202/HCESHC‑ab110410, MitoSci., 
mouse monoclonal, 1:5000); oxidative phosphorylation 
(ATP synthase‑α; MS604/D1848‑ab110413, MitoSci., 
mouse monoclonal, 1:5000); Ca++/calmodulin‑dependent 
protein kinase beta (CaMMκβ L‑19, sc‑9629, Santa Cruz 
Biotechnol., Inc, Santa Cruz, CA; goat polyclonal, 1:5000); 
protein phosphatase 2A (PP2A‑C α/β L‑19; sc‑81601/
J1410; Santa Cruz Biotechnol.; mouse monoclonal, 1:5000); 
AMPKα1/2 (sc‑25792, Santa Cruz Biotechnol.; rabbit 
polyclonal, 1:5000); phosphoAMPKα1/2 (pAMPK) (sc‑33524, 
Santa Cruz Biotechnol., rabbit polyclonal, 1:5000); acetyl 
CoA carboxylase (ACC) (3662S/4, Cell Signaling Technol., 
Danvers, MA; rabbit polyclonal, 1:5000); phosphoACC 
(pACC S79; 3661S/8, Cell Signaling; rabbit polyclonal, 1:5000); 
fatty acid synthase (FAS) (C2065; 3180S/2, Cell Signaling; 
rabbit polyclonal, 1:5000); and DβH (sc‑15318, Santa Cruz 
Biotechnol.; rabbit polyclonal, 1:500). DVC tissue was probed 
with PDH, SDH, and oxidative phosphorylation protein 
complex antisera to detect the following proteins: PDH: 
PDH‑E2 (72 kDa); PDH‑E2/E3bp (55 kDa); and PDH‑E1‑alpha 
(42 kDa); SDH: C‑V‑alpha (F1‑alpha; 53 kDa); C‑II‑30 (SDHB; 30 
kDa); and C‑II‑70 (SDHA; 70 kDa); oxidative phosphorylation: 
ATP synthase (Complex V) subunit alpha (CV‑alpha; 53 kDa); 
Fig. 1. Outline of experiment schedule and treatment group identification. Adult female rats were bilaterally ovariectomized (OVX) and implanted with 
a subcutaneous capsule (i.d. 1.58 mm, o.d. 3.18 mm; 10 mm/100 g bw) filled with 17β estradiol‑3‑benzoate (30 µg/mL safflower oil) or oil on day 1 of the 
study. On experiment days 6–8, rats were injected at 11.00 hr with vehicle (V) or neutral protamine Hagedorn insulin (I; 12.5 U/kg bw), one dose per day. 
On day 9, rats previously injected with V were given a final injection of V [n=4 estradiol‑implanted (E‑V4); n=4 oil‑implanted (O‑V4)]. At the same time, rats 
previously injected with I were given a V injection [n=4 estradiol‑implanted (E‑I3V); n=4 oil‑implanted (O‑I3V)] or a fourth I dose [n=4 estradiol‑implanted 
(E‑I4); n=4 oil‑implanted (O‑I4)]. 
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Q‑cytochrome c oxidoreductase (Complex III) subunit Core 
2 (CIII‑core 2; 47 kDa); Cytochrome c oxidase (Complex IV) 
subunit I (CIV‑I; 39 kDa); Succinate Dehydrogenase (Complex 
II) subunit 30 kDa (CII‑30; 30 kDa); and NADH‑coenzyme 
Q oxidoreductase (Complex I) subunit NDUFB8 (CI‑20; 
20 kDa). The loading control, α‑tubulin, was probed 
with mouse monoclonal antibodies (CP06; Calbiochem, 
Gibbstown, NJ; 1:2000). Membranes were incubated with 
peroxidase‑conjugated goat anti‑mouse (NEF822001EA; 
1:5000; Perkin Elmer, Boston, MA); goat anti‑rabbit 
(NEF812001EA; 1:5000; Perkin Elmer, Waltham, MA); or 
donkey anti‑goat (sc‑2020; 1:5000; Santa Cruz Biotechnol.) 
secondary antibodies, then exposed to Supersignal West 
Femto Maximum Sensitivity substrate (Thermo Fisher 
Scientific, Waltham, MA). Chemiluminescent signal was 
visualized in a Syngene G:box Chemi (Syngene USA, 
Frederick, MD). Immunoblot densities were quantified with 
AlphaImager HP V 5.0.1 software (Cell Biosciences; Santa 
Clara, CA); optical density (O.D.) values were normalized to 
α‑tubulin. Protein MW markers were included in each blot.
Blood analyte measurements
Blood glucose concentrations were measured with an 
AccuCheck Advantage glucometer (Roche diagnostics, 
Indianapolis, IN), as described (Kale et al. 2006). 
Plasma estradiol concentrations were determined by 
radioimmunoassay, as reported (Briski et al. 2001); assay 
sensitivity is approximately 1.5 pg/mL, with intra‑ and 
inter‑assay variabilities of 4.2 and 6.9%.
Statistics
Mean circulating glucose and estradiol concentrations 
and normalized protein O.D. measures were evaluated by 
two‑way ANOVA and Student‑Newman‑Keuls post‑hoc test. 
Differences of p<0.05 were considered significant.
RESULTS
Fig. 2 shows that estradiol‑ and oil‑implanted 
OVX rats injected with vehicle (V) over the four day 
experiment exhibited comparable blood glucose levels 
[E‑V4 vs. O‑V4] (F5,18=92.4, p<0.0001; insulin effect: F=230.9, 
p<0.0001). Injection of insulin (I) on study days 1–3 did 
not modify baseline glucose levels on day 4 in E‑I3V 
(vs. E‑V4), but glucose was elevated in O‑I3V compared 
to O‑V4. Treatment with a fourth of four doses of insulin 
suppressed blood glucose in E‑I4 and O‑I4 to an equivalent 
extent. Sc E‑filled capsule implantation resulted in 
plasma hormone concentrations of 21.4+0.3 (E‑V4), 
21.9+0.4 (E‑I3V), and 21.7+0.4 (E‑I4) pg/mL; circulating 
estradiol was undetectable in groups of OVX+oil rats.
Acclimation of rate‑limiting glycolytic, 
tricarboxylic acid cycle, and respiratory chain 
enzyme protein expression to hypoglycemia 
in A2 neurons: impact of estradiol
Fig. 3 illustrates effects of serial insulin injections 
on basal and hypoglycemic expression profiles for the 
glycolytic enzyme PFKL (Fig. 3A); the PDH subunit protein, 
E2/E3pb (Fig. 3B); tricarboxylic acid cycle enzymes, 
IDH2 (Fig. 3C) and OGDH (Fig. 3D); the respiratory chain 
Complex II protein subunit, C‑V‑alpha (Fig. 3E), and ATP 
synthase‑α (Fig. 3F) in cDVC A2 neurons. Data show that 
these proteins, excepting ODGH, were increased in E‑V4 
vs. O‑V4. Following insulin treatment on days 1–3, A2 
PFKL protein levels on day 4 (Fig. 3A) were elevated in 
E‑I3V, but not O‑I3V vs. respective V4 controls [F5,12=29.9, 
p<0.0001; estradiol effect: F=105.0, p<0.0001; insulin effect: 
F=20.0, p=0.001]. Day 4 Insulin injection did not alter this 
profile in E‑I4 or O‑I3V. Insulin dosing on days 1–3 did not 
alter PDH E2/E3 pb (Fig. 3B) protein expression on day 4 
(E‑I3V vs. E‑V4; O‑I3V vs. O‑V4) [F5,12=11.4, p=0.0003; estradiol 
effect: F=36.9, p<0.0001; insulin effect: F=9.97, p=0.003]. Yet, 
insulin injection on day 4 reduced PDH E2/E3 pb protein 
expression in E‑I4 and Oil‑I4. Figs 3C and 3D indicate that A2 
IDH2 [F5,12=11.2, p=0.003; estradiol effect: F=51.3, p<0.0001] 
and OGDH [F5,12=19.7, p<0.0001; estradiol effect: F=62.8, 
p<0.0001; insulin effect: F=4.82, p=0.03; estradiol and insulin 
interaction: F=13.0, p=0.001] proteins were unaltered in 
E‑I3V or O‑I3V vs. V4 controls. Insulin injection on day 4 did 
Fig.  2. Effects of precedent insulin (I) – induced hypoglycemia on blood 
glucose concentrations after I or vehicle (V) injection of estradiol‑ or 
oil‑implanted ovariectomized (OVX) female rats. Groups of OVX+estradiol 
(E) and OVX+oil (O) groups were injected as follows: 1) four doses of V, on 
as many days [n=4 E‑V4; n=4 O‑V4]; 2) three daily doses of I (12.5U neutral 
protamine Hagedorn insulin/kg bw sc), followed by V on day four [n=4 E‑I3V; 
n=4 O‑I3V]; or 3) four doses of I, one per day [n=4 E‑I4; n=4 O‑I4]. Bars depict 
mean blood glucose concentrations ±SEM at +2 hr after final treatments 
on day four. Data labeled with dissimilar letters differ statistically.
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Fig. 3. Effects of precedent hypoglycemia on basal and hypoglycemic patterns of A2 nerve cell energy metabolism enzyme protein expression in ovariectomized 
OVX+E vs. OVX+O female rats. Tyrosine hydroxylase (TH)‑immunolabeled A2 neurons from the caudal dorsal vagal complex of E‑V4 [solid grey bars], O‑V4 [solid 
white bars], E‑I3V [horizontal striped grey bars], O‑I3V [horizontal striped white bars], E‑I4 [diagonal striped grey bars], and O‑I4 [diagonal striped white bars] 
treatment groups (n=4 rats/group). Separate pooled lysates of n=50 A2 cells/group (n=12–13 neurons/rat) were analyzed by Western blot for the rate‑limiting 
glycolytic enzyme, phosphofructokinase (PFLK) (A); the pyruvate dehydrogenase complex subunit protein E2/E3 pb (B); the rate‑limiting tricarboxylic acid 
cycle enzymes, isocitrate dehydrogenase (IDH2) (C) and alpha ketoglutarate dehydrogenase (OGDH) (D); the respiratory chain complex II protein subunit, 
C‑V‑alpha (E), or ATP synthase‑α (F). Each protein analysis was carried out on triplicate lysate pools. Protein band optical densities (O.D.) were quantified with 
AlphaImager HP V 5.0.1 software, and expressed relative to the loading control, α‑tubulin. Graphs depict mean normalized O.D. values ±SEM for each protein 
for each treatment group. Representative immunoblots are shown below each graph. Data labeled with dissimilar letters differ statistically.
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not modify IDH2 expression, but respectively increased or 
decreased OGDH in E‑I4 or O‑I4. Fig. 3E shows that C‑V‑alpha 
protein was lower in E‑I3V vs. E‑V4, but equivalent in O‑I3V 
vs. O‑V4; insulin dosing on day 4 elevated this profile 
in both E‑I4 and O‑I4 [F5,12=7.80, p=0.002; estradiol effect: 
F=20.6, p=0.0007; insulin effect: F=6.48, p=0.012]. Data in 
Fig. 3F show respective inhibitory or stimulatory effects 
of precedent insulin dosing on A2 ATP synthase‑α protein 
[F5,12=22.2, p<0.0001]. Insulin injection on day 4 did not alter 
(E‑I4) or inhibited (O‑I4) this profile [estradiol effect: F=92.6, 
p<0.0001; insulin effect: F=7.03, p=0.009].
Acclimation of caudal dorsal vagal complex 
pyruvate dehydrogenase, complex II, and 
respiratory chain complex I‑V enzyme protein 
profiles to hypoglycemia: impact of estradiol
Figs 4A–4D illustrates precedent insulin dosing effects 
on cDVC PDH subunit protein expression in estradiol‑ vs. 
oil‑implanted OVX rats. Fig. 4A depicts representative 
immunoblots of PDH‑E2 (72 kDa), PDH‑E2/E3bp (55 kDa), 
PDH‑E1‑α (42 kDa), and α‑tubulin proteins in E‑V4; O‑V4; 
E‑I3V; O‑I3V; Est/I4; and Oil/I4 cDVC tissue. Fig. 4B [PDH‑E2: 
F5,12=24.1, p<0.0001; estradiol effect: F=99.3, p<0.0001; insulin 
effect: F=8.27, p=0.0055], Fig. 4C [PDH‑E2/E3bp: F5,12=87.3, 
p<0.0001; estradiol effect: F=33.0, p<0.0001; insulin effect: 
F=45.1, p<0.0001]; estradiol and insulin interaction: F=7.45, 
p=0.008], and 4.D [PDH‑E1‑α: F5,12=5.40, p=0.008; estradiol effect: 
F=22.7, p=0.0005] show that each subunit was elevated in E‑V4 
vs. O‑V4. Precedent insulin dosing did not modify baseline 
protein subunit expression, but PDH‑E2 and PDH‑E1‑α 
proteins were diminished in E‑I4 but not O‑I4. Fig. 4E depicts 
representative immunoblots of complex II subunit C‑II‑70 
(SDHA; 70 kDa), C‑V‑alpha (F1‑alpha; 53 kDa), C‑II‑30 (SDHB; 
30 kDa), and α‑tubulin in cDVC tissue. Data in Panels 4.F 
[C‑II‑70: F5,12=4.94, p=0.011; estradiol effect: F=19.7, p=0.001], 
4.G [C‑V‑alpha: F5,12=7.986, p=0.002; estradiol effect: F=24.7, 
p=0.0003; insulin effect: F=4.19, p=0.042], and 4.H [C‑II‑30: 
F5,12=5.16, p=0.009; estradiol effect: F=14.0, p=0.003; insulin 
effect: F=5.18, p=0.023] show that subunit levels were elevated 
in E‑V4 vs. O‑V4. Precedent hypoglycemia did not alter baseline 
or hypoglycemia‑induced patterns of SDH subunit expression. 
Panel 4.I depicts representative immunoblots of Complex V 
(CV) ATP synthase‑α (53 kDa), Complex III (CIII) subunit Core 2 
(CIII‑core 2; 47 kDa), Complex IV (CIV) subunit I (CIV‑I; 39 kDa), 
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Complex II (CII) subunit 30 kDa (CII‑30; 30 kDa), and Complex I 
(CI) subunit NDUFB8, CI‑20 (20 kDa) proteins detected in cDVC 
tissue from estradiol‑ and oil‑implanted OVX rats. Quantitative 
data show that cDVC ATP synthase‑subunit alpha [Fig. 4J; 
F5,12=4.51, p=0.015; estradiol effect: F=16.3, p=0.002], CIII‑core 
[Fig. 4K; F5,12=34.4, p<0.0001; estradiol effect: F=81.4, p<0.0001], 
CIV [Fig. 4L; F 5,12=17.1, p<0.0001; insulin effect: F=27.1, p<0.0001; 
estradiol and insulin interaction: F=5.92, p=0.016], CII‑30 
[Fig. 4M; F5,12=3.91, p=0.025; insulin effect: F=9.34, p=0.004], and 
CI [Fig. 4N; F5,12=11.7, p=0.0003; estradiol effect: F=6.63, p=0.024; 
insulin effect: F=24.5, p<0.0001] levels were higher in E‑V4 vs. 
O‑V4. Precedent hypoglycemia elevated CIV‑I expression in 
O‑I3V, reduced CIII levels in E‑I3V, and increased ATP synthase‑α 
in O‑I3V. Insulin injection on day 4 decreased CIV‑I, CII‑30, and 
CI‑20 profiles in E‑ and O‑I4, but only reduced CIII‑core 2 and 
ATP synthase‑α proteins in the latter.
Acclimation of A2 neuron AMPK and upstream 
kinase and phosphatase protein expression to 
hypoglycemia: impact of estradiol
Figs 5A and 5B depict effects of daily insulin dosing 
on A2 neuron AMPK and pAMPK proteins. Data show 
that precedent insulin dosing did not modify AMPK 
[F5,12=29.742, p<0.0001; estradiol effect: F=5.99, p=0.031; 
insulin effect: F=64.9, p<0.001; estradiol and insulin 
interaction: F=6.51, p=0.012] or pAMPK [F5,12=15.7, 
p<0.0001; estradiol effect: F=16.5, p=0.023; insulin effect: 
F=35.4, p<0.0001; estradiol and insulin interaction: F=9.23, 
p=0.002] levels. A fourth insulin injection significantly 
augmented both proteins, albeit to a greater extent in 
O‑I4 vs. E‑I4 Data in Figs 5C and 5D show that the upstream 
kinase, CaMMκβ [F5,12=25.305, p<0.0001; estradiol effect: 
F=19.1, p<0.0001] and upstream phosphatase, protein 
phosphatase 2A (PP2A) [F5,12=23.9, p<0.0001; estradiol 
effect: F=87.1, p<0.0001; insulin effect: F=15.3, p=0.0005] 
are correspondingly elevated or diminished in O‑V4 vs. 
E‑V4. Insulin dosing on days 1–3 did not modify either 
profile. Insulin injection on day 4 did not change 
CaMMκβ expression, but suppressed PP2A expression in 
E‑I4. Figs 5E and 5F show that precedent hypoglycemia 
had no effect on ACC [F5,12=19.0, p<0.0001; estradiol effect: 
F=28.3, p=0.0002; insulin effect: F=32.3, p<0.0001] or pACC 
[F5,12=10.5, p=0.0005; estradiol effect: F=30.865, p=0.0001; 
estradiol and insulin interaction: F=8.41, p=0.005] 
expression in E‑I3V (vs. E‑V4), but correspondingly 
increased and decreased these proteins in O‑I3V vs. 
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O‑V4. Insulin injection on day 4 increased ACC and pACC 
profiles in E‑I4, but not O‑I4. Data in Fig. 5G show that FAS 
protein levels [F5,12=6.69, p=0.003; estradiol effect: F=17.6, 
p=0.001; insulin effect: F=4.75, p=0.03] were refractory to 
precedent insulin administration, but were augmented 
by insulin dosing on day 4 in E‑I4, but not in Oil‑I4.
Acclimation of A2 neuron DβH enzyme protein 
expression to hypoglycemia: impact of estradiol
Fig. 6 shows that DβH protein expression was higher 
in E‑V4 vs. O‑V4 [F5,12=36.2, p<0.0001; insulin effect: F=7.33, 
p=0.008; estradiol and insulin interaction: F=82.8, p<0.0001]. 
Fig. 4. Effects of precedent hypoglycemia on basal and hypoglycemic patterns of caudal dorsal vagal complex (cDVC) pyruvate dehydrogenase (PDH), 
succinate dehydrogenase (SDH), and respiratory chain complex subunit protein expression in ovariectomized OVX+estadiol vs. OVX+oil female rats. cDVC 
aliquots for each treatment group (n=4 rats/group) were evaluated for PDH complex proteins; analyzes were performed on separate triplicate aliquots. 
Representative immunoblots in Fig. 4A show that PDH‑E2, PDH‑E2/E3bp, and PDH‑E1‑alpha subunits were detected in each treatment group. Bar graphs 
show mean normalized O.D. values ±SEM (n=4/group) for cDVC 72 kDa (B), 55 kDa (C), and 42 kDa (D) PDH subunit expression for the following treatment 
groups: E‑V4 [solid grey bars], O‑V4 [solid white bars], E‑I3V [horizontal striped grey bars], O‑I3V [horizontal striped white bars], E‑I4 [diagonal striped grey 
bars], and O‑I4 [diagonal striped white bars]; data labeled with dissimilar letters show statistical difference. The SDH subunit immunoblot in Fig. 4E shows 
that C‑V‑alpha (53 kDa), C‑II‑30 (30 kDa), and C‑II‑70 (70 kDa) proteins were detectable in cDVC tissue from OVX+estradiol and OVX+oil rats. Bar graphs in 
Figs 4F–4H depict mean normalized O.D. values ±SEM for cDVC 70 kDa, 53 kDa, and 30 kDa subunit proteins, respectively. The immunoblot in Fig. 4I shows 
that Complex V (CV) ATP synthase‑subunit alpha (53 kDa), Complex III (CIII) subunit Core 2 (CIII‑core 2; 47 kDa), Complex IV (CIV) subunit I (CIV‑I; 39 kDa), 
Complex II (CII) subunit 30 kDa (CII‑30; 30 kDa), and Complex I (CI) subunit NDUFB8, CI‑20 (20 kDa) were each detected in cDVC tissue from estradiol‑ or 
oil‑implanted OVX rats. Mean O.D. values ±SEM for cDVC Complex I‑V protein subunit expression are presented in Fig. 4J (ATP synthase‑subunit alpha), 
Fig. 4K (cDVC CIII‑core), Fig. 4L (cDVC CIV‑I), Fig. 4M (cDVC CII‑30), and Fig. 4N (cDVC CI‑20). Data show that PDH enzyme subunits were down‑regulated 
in E‑V4 vs. O‑V4. Baseline protein profiles were refractory to prior hypoglycemia, but PDH‑E2 and PDH‑E1‑alpha proteins were reduced in E‑I4 but not O‑I4 
in response to a final bout of hypoglycemia. Prior hypoglycemia did not modify baseline or hypoglycemia‑induced patterns of SDH subunit expression. 
Moreover, precedent hypoglycemia elevated basal CIV‑I expression in O‑I3V; decreased CIII protein levels in E‑I3V; and elevated ATP synthase profiles in 
both E‑ and O‑I3V. A final hypoglycemic bout decreased CIV‑I, CII‑30, and CI‑20 in both E‑ and O‑I4, but only reduced CIII‑core 2 and ATP synthase in O‑I4. 
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Insulin dosing on days 1–3 correspondingly increased or 
decreased this protein in E‑I3V or O‑I3V. Insulin injection on 
day 4 further inhibited or augmented this profile in E‑I4 and 
O‑I4, respectively. 
DISCUSSION
The current studies investigated the hypothesis that 
estradiol regulation of recurring hypoglycemia on A2 
catecholamine neurotransmitter synthesis correlates with 
neuro‑protective effects of this hormone on energy metabolic 
pathway function during and between bouts of hypoglycemia. 
Precedent exposure to serial bouts of hypoglycemia caused 
opposite changes in basal A2 neuron DβH protein expression in 
estradiol‑ vs. oil‑implanted OVX female rats, plus exacerbation 
of these divergent adjustments by renewed hypoglycemia. 
As these cells communicates hypoglycemia‑associated cell 
energy imbalance signaling (Gujar et al. 2014; Shrestha et 
al. 2014), estradiol‑dependent adaptive down‑regulation of 
noradrenergic neurotransmission by A2 neurons implies that 
this hormone may promote a positive energy state during this 
recurring metabolic stress. Estradiol also regulates effects 
of recurrent hypoglycemia on enzyme proteins involved 
in energy metabolism and fatty acid synthesis. As A2 cells 
exhibit elevated baseline expression of the rate‑limiting 
glycolytic enzyme PFKL in the aftermath of hypoglycemia, 
coincident with diminished C‑V‑alpha and ATP synthase‑α 
protein profiles, estradiol may stimulate glycolysis, yet 
suppress mitochondrial aerobic respiration/energy 
production. During the fourth of four daily hypoglycemic 
episodes, estradiol permitted OGDH up‑regulation and 
prevented down‑regulation of ATP synthase‑α, implying 
that it may beneficially alleviate energy state negativity 
in A2 cells during re‑exposure to this stress. This view is 
bolstered by evidence that A2 AMPK activation is greater 
in O vs. E rats in response to recurring hypoglycemia. Taken 
together, current data suggest that estradiol‑mediated 
reductions in A2 noradrenergic signaling may reflect, in part, 
energetic resilience of these cells to recurring hypoglycemia. 
Further research is needed to determine effects of adaptive 
adjustments in between‑hypoglycemia A2 neurotransmission 
on glucostatic and non‑glucostatic functions governed by 
this cell group. 
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Acclimation of rate‑limiting glycolytic, 
tricarboxylic acid cycle, and respiratory chain 
enzyme protein expression to hypoglycemia in A2 
neurons: impact of estradiol
Precedent hypoglycemia exerts divergent, e.g. 
stimulatory or inhibitory effects on A2 PFKL vs. C‑V‑alpha 
and ATP synthase‑α protein profiles in the E‑I3V treatment 
group. Adaptive augmentation of baseline PFKL expression 
reported here is accompanied by a loss of this positive 
reaction to hypoglycemia in E‑I4 (Tamrakar et al. 2015). 
These results suggest that estradiol may enhance glycolytic 
yield of ATP and NADH, while diminishing mitochondrial 
fuel catabolism and aerobic respiration in the aftermath 
of this stress. In contrast, augmentation of basal ATP 
synthase‑α protein expression in post‑hypoglycemic 
OVX+oil rats implies that, in the absence of estradiol, 
increased energy output may occur via oxidative 
phosphorylation as A2 cells recover from hypoglycemia. 
In Est/I4 group, renewed exposure to hypoglycemia, e.g. 
induction of a fourth daily bout, did not further modify 
A2 PFKL expression relative to the heightened day four 
baseline, suggesting that the glycolytic pathway may adopt 
a heightened steady‑state that is refractory to recurring 
hypoglycemic episodes. Re‑exposure to hypoglycemia 
on day four suppressed the 55 kDa PDH complex subunit 
protein E2/E3 pb below baseline in A2 cells from both 
estradiol‑ and oil‑implanted OVX rats, an acquired negative 
response that is estrogen‑independent. A2 neurons 
may thus develop a lesser need for glycolysis‑derived 
substrate for mitochondrial aerobic respiration during 
recurring hypoglycemia. A fourth hypoglycemic bout did 
not elevate A2 ATP synthase‑α protein levels relative to 
now‑diminished basal profiles in E‑I4, but suppressed this 
protein below baseline in O‑I4, inferring that mitochondrial 
energy production may adaptively down‑regulate in the 
latter treatment group. Since acute hypoglycemia did not 
modify ATP synthase‑α expression in E or O (Tamrakar et 
al. 2015), current results infer continuation of this lack of 
response in E‑I4 and development of negative reactivity 
in O‑I4. Results also demonstrate sustained hypoglycemic 
up‑regulation of the tricarboxylic acid cycle enzyme 
OGDH in E‑I4 rats, but inhibition of this protein profile 
by recurring hypoglycemia in O‑I4, amounting to gain of 
negative response. These findings suggest that estradiol 
may promote an ongoing need for non‑energy derivative 
Krebs cycle products. It should be noted that up‑ or 
down‑regulation of A2 enzyme protein expression is not 
automatic proof of corresponding increases and decreases 
in enzyme activity; however, prior evidence for correlated 
increases in metabolic enzyme expression and activity 
due to estradiol treatment supports the plausibility of 
that outcome (Irwin et al. 2008). Affirmation of effects 
of recurring hypoglycemia on basal and hypoglycemic 
patterns of A2 enzyme activity awaits the development 
Fig.  5. Effects of precedent hypoglycemia on basal and hypoglycemic 
patterns of A2 nerve cell adenosine 5’‑monophosphate‑activated protein 
kinase (AMPK), phosphoAMPK (pAMPK), Ca++/calmodulin‑dependent 
protein kinase beta (CaMMκβ), protein phosphatase‑2A (PP2A), acetyl 
CoA carboxylase (ACC), phosphoACC (pACC), and fatty acid synthase 
(FAS) protein expression in estradiol‑ vs. oil‑implanted ovariectomized 
female rats. Separate pooled lysates of n=50 A2 cells/treatment group 
(n=12–13 neurons/rat) were analyzed by Western blot for AMPK (A); 
pAMPK (B); CaMMκβ (C), PP2A (D), ACC (E), pACC (F), or FAS (G). Each 
protein analysis was performed on triplicate lysate pools. Graphs 
depict mean normalized protein O.D. values ±SEM for E‑V4 [solid grey 
bars], O‑V4 [solid white bars], E‑I3V [horizontal striped grey bars], O‑I3V 
[horizontal striped white bars], E‑I4 [diagonal striped grey bars], and 
O‑I4 [diagonal striped white bars] treatment groups. Representative 
immunoblots are shown below each graph. Data labeled with dissimilar 
letters show statistical difference. 
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of analytical methods of requisite sensitivity for analysis 
of small‑size neuron pool samples equivalent to those 
evaluated here.
Acclimation of A2 neuron AMPK and upstream 
kinase and phosphatase protein expression to 
hypoglycemia: impact of estradiol
Precedent hypoglycemia did not modify day four 
baseline pAMPK protein profiles in A2 neurons from 
estradiol‑ or oil‑implanted OVX rats. In the absence of 
correlative information on post‑hypoglycemic A2 cell 
ATP content, we speculate that steady‑state energy 
levels in these cells may be preserved despite adaptive 
changes in energy pathway enzyme expression. ATP 
stores are likely to remain unchanged if net increases or 
reductions in ATP output are matched by parallel up‑ or 
downsizing of energy utilization. During the fourth of 
four hypoglycemia bouts, A2 pAMPK protein levels were 
elevated in both E‑I4 and O‑I4, albeit to a significantly 
greater extent in the latter. These results suggest 
that precedent hypoglycemia may render A2 neurons 
vulnerable to energy instability during re‑exposure, 
but that extent of energy deficiency may be attenuated 
by estradiol. We previously reported that estradiol 
promotes deactivation of AMPK during chronic 
hypoglycemia (Cherian and Briski 2012). A critical 
Fig. 6. Effects of precedent hypoglycemia on basal and hypoglycemic patterns of A2 nerve cell dopaminebBeta‑hydroxylase (DβH) protein expression in 
estradiol‑ vs. oil‑implanted ovariectomized female rats. For each treatment group, pooled lysates of n=50 A2 neurons (n=12–13 neurons/rat) were analyzed by 
Western blot for DβH in triplicate. Data show mean normalized DβH O.D. values ±SEM for E‑V4 [solid grey bars], O‑V4 [solid white bars], E‑I3V [horizontal striped 
grey bars], O‑I3V [horizontal striped white bars], E‑I4 [diagonal striped grey bars], and O‑I4 [diagonal striped white bars] groups. Representative immunoblots 
are presented below the graph. Data labeled with dissimilar letters differ statistically. The insert to Fig.  6 shows the effect of acute insulin‑induced 
hypoglycemia on A2 neuron DβH protein levels. Bars show mean O.D. values ±SEM for oil and estradiol groups given four consecutive daily vehicle injections 
[n=4 E‑V4 (grey bar); n=4 O‑V4 (white bar)] or treated with vehicle on days 1–3, then injected with I on day four [n=4 E‑V3I (horizontal‑stripe grey bar); n=4 O‑V3I 
(horizontal‑striped white bar)]. Data show that a single hypoglycemic episode decreased mean DβH protein in both estradiol‑ and oil‑implanted rats. 
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difference between that study and the present work 
studies is improved sensitivity of immunocytochemical 
methodology for identification of cDVC TH‑ir neurons 
in hindbrain cryosections, as reflected by higher 
numbers of collectable A2 cells per individual animal, 
resulting in sufficient numbers of pools for quantitative 
protein analysis in the present research. Thus, prior 
results may reflect, in part, the distinctive reactivity 
of a subset of A2 cells characterized by relatively high 
neurotransmitter content. 
Estradiol may function to prevent adaptation 
of upstream AMPK‑regulating protein kinase and 
phosphatase enzymes to recurring hypoglycemia. A fourth 
of four hypoglycemic bouts did not modify A2 CaMMκβ 
protein content in E‑I4 or O‑I4, but diminished PP2A 
levels only in the former group. As a single hypoglycemic 
episode was previously observed to increase CaMMκβ and 
reduce PP2A protein profiles in OVX+oil rats (Tamrakar 
et al. 2015), current data suggest that when estradiol is 
absent, precedent exposure eliminates these responses. 
As we did not directly compare incremental changes in 
AMPK activity in acute vs. chronic hypoglycemic rats, 
we do not know if precedent hypoglycemia alters the 
magnitude of A2 energy debilitation in OVX+oil rats. In 
light of aforementioned adaptive loss of facilitative kinase 
and inhibitory phosphatase protein responses to renewed 
hypoglycemia in O‑I4 rats, cellular reductions in ATP may 
play a relatively greater role in AMPK activation during 
recurring vs. acute hypoglycemia in that group. Precedent 
hypoglycemia did not alter basal A2 ACC or pACC protein 
profiles in E‑I3V1, but respectively increased or decreased 
these proteins in O‑I3V. These data imply that when 
estradiol is absent, ACC activity may be enhanced amidst 
bouts of repeated hypoglycemia; the possibility that this 
outcome coincides with augmented cellular malonyl CoA 
accumulation and decreased fatty acid oxidation awaits 
experimental verification. Renewed hypoglycemia on day 
four elevated both profiles in E‑I4 without effect in O‑I4, 
suggesting that in the latter this enzyme acquires a new 
state of heightened activity that is refractory to recurring 
hypoglycemia. A potential ensuing lack of change in 
malonyl CoA levels may impede fatty acid utilization for 
energy. Acute hypoglycemia had no effect on ACC, pACC, or 
FAS protein profiles in estradiol‑ or oil‑implanted OVX rats 
(Tamrakar et al. 2015); current observations of concurrent 
augmentation of ACC and FAS protein profiles in the E‑I4 
group imply a gain in positive reactivity of these proteins 
in this group. 
As the DVC is comprised of multiple neuron 
neurotransmitter phenotypes, analyses of mitochondrial 
complex enzyme protein subunit expression in whole 
DVC samples shed light on whether patterns of A2 nerve 
cell protein adaptation to recurring hypoglycemia are 
representative or uncommon in this neural structure. 
For example, DVC PDH‑E2 and PDH‑E1‑α subunit protein 
profiles acquire negative reactivity in E‑I4 but not O‑I4; 
yet, A2 PDH‑E2 protein is down‑regulated by acclimation 
in both E‑I4 and O‑I4, inferring that negative A2 adaptation 
in the absence of estradiol is atypical of the DVC. DVC and 
A2 neuron samples also showed differential habituation of 
the Complex II subunit C‑V‑alpha, as baseline expression 
of this protein was respectively unchanged or decreased in 
these samples from E‑I3V rats, and recurring hypoglycemia 
increases protein levels in A2 neurons but not whole DVC in 
O‑I4. Precedent hypoglycemia elevated synthase‑α protein 
in the O‑I3V DVC and O‑I3V A2 neurons, but decreased this 
protein in E‑I3VA2 cells. 
Observations of estradiol‑mediated augmentation of 
basal DβH protein expression concur with evidence that 
estrogen stimulates DβH mRNA expression in rat brain 
(Senova et al. 2002). Modifications in A2 DβH protein levels 
in estradiol‑ vs. oil‑treated rats one day following serial 
exposure to hypoglycemia reflect a persistent impact of that 
prior experience on baseline catecholamine biosynthesis 
despite recovery from hypoglycemia. Data demonstrating 
a decline vs. increase in this protein profile in E‑ vs. 
O‑I3V groups concur with previous reports of divergent 
changes in A2 DβH mRNA after precedent hypoglycemia 
(Cherian and Briski 2012), implying that neurotransmitter 
production may be reduced or augmented between bouts 
of recurring hypoglycemia, at least within post‑recovery 
time frame examined here. It should be noted that protein 
analyses were performed 2 hr after initiation of the final 
hypoglycemic episode; thus, the possibility (particularly 
in the presence of estrogen) that DβH levels measured 
at this time point may reflect rebound from a preceding 
stimulatory response that occurred between time zero and 
sampling, while this protein profile remains elevated in the 
absence of estradiol cannot be discounted. Further research 
is needed to evaluate ramifications of estradiol‑dependent 
acclimation of between‑hypoglycemia A2 nerve cell 
signaling on neural functions controlled by this cell group. 
Exacerbation of adjustments in baseline DβH protein 
expression by a fourth daily hypoglycemic episode implies 
that potential deviations in A2 noradrenergic signaling may 
be corresponding heightened during renewed exposure 
to this metabolic stress. Hypoglycemia poses a significant 
risk of brain injury as a continuous glucose supply is 
needed to provide sufficient energy to maintain neuron 
transmembrane ion gradients. Rigorous glycemic control 
is crucial for ideal management of insulin‑dependent 
diabetes mellitus (IDDM), but is complicated by recurring 
iatrogenic insulin‑induced hypoglycemia (Cryer 2008, 
2011). In IDDM patients, recurring hypoglycemia elicits 
hypoglycemia‑associated autonomic failure, which results 
in severe, unrelieved hypoglycemia due to maladaptive 
diminishment of glucose counter‑regulatory outflow and 
neurogenic unawareness (Cryer 2005). Current results 
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bolster the need for additional research to investigate 
effects of adaptive down‑ vs. up‑regulation of A2 nerve 
cell signaling in the presence vs. absence of estradiol on 
metabolic as well as non‑metabolic functions that rely 
upon in input from this cell group between and during 
bouts of ongoing hypoglycemia in patients prone to this 
therapy complication. 
Acclimation of A2 neuron DβH enzyme protein 
expression to hypoglycemia: impact of estradiol
This study did not affirm our prediction of parallelism 
of adaptation of A2 nerve cell DβH protein expression and 
DVC Fos immunolabeling (Nedungadi et al. 2006) in both 
estradiol‑ and oil‑implanted OVX rats. Rather, evidence 
for divergence of these two parameters, independent of 
estradiol status, detracts from our working assumption 
that hypoglycemia‑induced DVC Fos immunoreactivity is 
a reliable indicator of metabolo‑sensory neuron signaling. 
Further work is needed to identify AP‑1 – controlled 
nerve cell transcriptional activities that habituate in an 
estradiol‑dependent manner to precedent hypoglycemia 
and consequent effects on A2 function.
The female lifespan includes transition between 
different reproductive states, e.g. juvenile quiescence, 
fecundity, and senescence, typified by unique patterns of 
ovarian estrogen secretion. Current results emphasize the 
need to understand how dissimilar physiological patterns 
of estradiol output, including variations in hormone 
secretion that occur over estrous cycle and pregnancy, 
as well as states of low estrogen output before and after 
fecundity may influence A2 neuron energetic habituation 
to recurring hypoglycemia. 
CONCLUSIONS
The present studies demonstrate that estradiol 
permits amplification of A2 nerve cell expression of key 
glycolytic, Krebs cycle, oxidative phosphorylation, and 
acetyl CoA‑FAS pathway enzyme proteins during recurring 
hypoglycemia. Between hypoglycemic bouts, A2 cells 
may acquire, when estradiol is present, heightened needs 
for glycolytic metabolites or derived energy, coincident 
with decreased reliance upon oxidative phosphorylation. 
Estrogen‑mediated prevention of maladaptive decline in 
ODGH and ATP synthase‑α expression during recurring 
hypoglycemia may contribute to energetic resilience to 
this persistent metabolic insult. Opposite direction of 
DβH habituation to recurring hypoglycemia in estradiol‑ 
vs. non‑steroid‑replaced OVX female rats implies that 
potential acclimation of A2 signaling to this stress is 
hormone‑dependent. 
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